Value of Manchester Acute Coronary Syndromes Decision Rule in the Detection of Acute Coronary Syndrome; a Systematic Review and Meta-Analysis

Fatemeh Ramezani1, Sajjad Ahmadi2, Gholamreza Faridaalae3, Alireza Baratloo4, Mahmoud Yousefifard1∗

1. Physiology Research Center, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
2. Emergency Medicine Department, Maragheh University of Medical Sciences, Maragheh, Iran.
3. Department of Health, Maragheh University of Medical Sciences, Maragheh, Iran.
4. Emergency Department, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Received: October 2018; Accepted: October 2018; Published online: 15 December 2018

Abstract: Introduction: There is still no consensus on the value of Manchester Acute Coronary Syndromes (MACS) decision rule in detecting acute coronary syndrome (ACS). Therefore, the purpose of the present systematic review and meta-analyses is to summarize the clinical evidence in the evaluation of the value of MACS in the diagnosis of ACS. Methods: A literature search was performed on the Medline, Embase, Scopus, and Web of Science databases. Outcomes included acute myocardial infarction (AMI) and major adverse cardiac event (MACE). Data were analyzed in the STATA 14.0 statistical program and the results were reported as summary receiver operating characteristics (SROC), sensitivity, specificity, positive and negative likelihood ratio, and diagnostic odds ratio with 95% confidence interval (95% CI). Results: Finally, 8 articles included in the meta-analysis. The area under the SROC of MACS was excellent in rule out of AMI (AUC = 0.99, 95% CI: 0.97 to 0.99) and MACE (AUC = 0.97, 95% CI: 0.95 to 0.98). The sensitivity and specificity of the troponin-only MACS / history electrocardiogram alone MACS (HE-MACS) in the rule out of AMI were 0.99 (95% CI: 0.98-0.99) and 0.22 (95% CI: 0.11-0.37), respectively, and for the original MACS were in order 0.99 (95% CI: 0.98-0.99) and 0.26 (95% CI: 0.20-0.34). The sensitivity and specificity of the troponin-only MACS / HE-MACS in the rule out of MACE were 0.94 (95% CI: 0.92-0.96) and 0.22 (95% CI: 0.12-0.39) compared to the 0.99 (95% CI: 0.98-0.99) and 0.27 (95% CI: 0.22-0.33) for the original MACS. Conclusion: The findings of this study showed that original MACS, troponin-only MACS, and HE-MACS are able to rule out AMI and MACE. However, further studies are needed in developing countries to confirm its external validity.

Keywords: Acute Coronary Syndrome; Decision Support Techniques; Diagnosis

© Copyright (2018) Shahid Beheshti University of Medical Sciences

Cite this article as: Ramezani F, Ahmadi S, Faridaalae Gh, Baratloo A, Yousefifard M. Value of Manchester Acute Coronary Syndromes Decision Rule in the Detection of Acute Coronary Syndrome; a Systematic Review and Meta-Analysis. Emergency. 2018; 6(1): e61.

1. Introduction

Acute coronary syndrome (ACS) is a leading cause of mortality and disability worldwide. According to the statistics, in 2017, about 18 million deaths from cardiovascular disease have occurred in the world, which has increased by 21.1% over the past 10 years (1). This increase in the burden of cardiovascular disease has led researchers to seek solutions to reduce the incidence of ACS. Early diagnosis of ACS is one of the most effective methods to reduce the burden of the disease (2). Currently, the patient’ clinical examination, electrocardiography and serial troponin are the standard ACS diagnostic method. A golden standard for diagnosing ACS in emergency episodes is the serial troponin test (3). However, the long-term approach to diagnosing ACS (about 6-12 hours) is the most important weakness of the current guidelines. In order to overcome this problem, Body et al in 2014 provided the Manchester Acute
Coronary Syndromes (MACS) decision rule to the diagnosis of ACS (4). In subsequent studies, the diagnostic value of this model was validated and modifications were made (5-9) (Table 1). In recent years, troponin-only MACS and history and electrocardiogram only MACS (HE-MACS) were introduced to overcome MACS shortcoming. However, there is still no comprehensive overview showing the performance of MACS and its modifications in rule out of ACS. Therefore, the purpose of the current systematic review and meta-analysis is to summarize the clinical evidence in assessing the value of MACS in the diagnosis of ACS.

2. Methods:

2.1. Search strategy

In the present meta-analysis using the keywords related to Manchester Acute Coronary Syndromes score in combination with Acute Coronary Syndrome, a search was performed in the Medline, Embase, Scopus, and Web of Science databases. The search was completed by the end of October 2018. No language restrictions were applied. The Searcy query for Medline (via PubMed) has been reported. 1- "Decision Support Techniques"[tiab] OR "Manchester Acute Coronary Syndromes"[tiab] OR "MACS prognostic modes"[tiab] OR "MACS prognostic models"[tiab] OR "MACS Rule"[tiab] OR "decision rule"[tiab] OR "Decision Support Techniques"[tiab] OR "Decision Support Technique"[tiab] OR "Technique, Decision Support"[tiab] OR "Techniques, Decision Support"[tiab] OR "Decision Support Technics"[tiab] OR "Decision Support Technic"[tiab] OR "Technic, Decision Support"[tiab] OR "Technics, Decision Support"[tiab] OR "Decision Aids"[tiab] OR "Aid, Decision"[tiab] OR "Aids, Decision"[tiab] OR "Decision Aid"[tiab] OR "Models, Decision Support"[tiab] OR "Decision Support Model"[tiab] OR "Decision Support Models"[tiab] OR "Model, Decision Support"[tiab] OR "Decision Analysis"[tiab] OR "Analyses, Decision"[tiab] OR "Decision Analyses"[tiab] OR "Analysis, Decision"[tiab] OR "Decision Modeling"[tiab] OR "Modeling, Decision"[tiab] OR "Clinical Prediction Rule"[tiab] OR "Clinical Prediction Rules"[tiab] OR "Prediction Rule, Clinical"[tiab] OR "Prediction Rules, Clinical"[tiab] OR "Rule, Clinical Prediction"[tiab] OR "Rules, Clinical Prediction"[tiab] OR "Acute Coronary Syndrome"[mh] OR "Myocardial Ischemia"[mh] OR "Angina Pectoris"[mh] OR "Angina, Stable"[mh] OR "Angina, Unstable"[mh] OR "Coronary Artery Disease"[mh] OR "Coronary Occlusion"[mh] OR "Coronary Stenosis"[mh] OR "Coronary Thrombosis"[mh] OR "Coronary Vasospasm"[mh] OR "Myocardial Infarction"[mh] OR "Anterior Wall Myocardial Infarction"[mh] OR "Inferior Wall Myocardial Infarction"[mh] OR "Non-ST Elevated Myocardial Infarction"[mh] OR "ST Elevation
2.2. Selection criteria

Inclusion criteria included relevant studies in the assessment of MACS in rule out of acute myocardial infarction (AMI) and major acute cardiac event (MACE). Exclusion criteria included the lack of the required data after contact with the authors, duplicate articles, and reviews.

2.3. Data syntheses and quality control

The method of summarizing and collecting data has been reported by previous systematic reviews (10-25). In summary, two independent reviewers screened the titles and abstracts as well as full text of the articles and selected relevant studies.
### Table 1: Manchester Acute Coronary Syndromes score (MACS)

| Original MACS | Troponin-only MACS | HE-MACS |
|---------------|--------------------|---------|
| 1- Heart-type fatty acid binding protein | ✓ | —– |
| 2- High sensitivity troponin T | ✓ | ✓ | ✓ |
| 3- ECG ischaemia | ✓ | ✓ | ✓ |
| 4- Sweating observed | ✓ | ✓ | ✓ |
| 5- Vomiting | ✓ | ✓ | ✓ |
| 6- Systolic blood pressure <100 mmHg | ✓ | ✓ | ✓ |
| 7- Worsening angina | ✓ | ✓ | —– |
| 8- Pain radiating to right arm or shoulder | ✓ | ✓ | ✓ |
| 9- Current tobacco smoker | —– | —– | ✓ |
| 10- Age | —– | —– | —– |
| 11- Male sex | —– | —– | ✓ |

### Table 2: Characteristics of included studies

| Author; year; country | Age | Sample size | Male | Type of study | Timing of blood sample | Sampling | Type of MACS | Outcome | Follow-up (day) |
|-----------------------|-----|-------------|------|---------------|------------------------|----------|--------------|---------|----------------|
| Alghamdi; 2018; UK    | Adult | 1902        | 1160 | Derivation-validation cohort | 0 | Consecutive | HE-MACS | MACE | 30 |
| Body; 2014; UK        | Adult | 1161        | 699  | Derivation-validation cohort | 0 | Consecutive | Original MACS | AMI; MACE | 30 |
| Body; 2015; UK        | Adult | 456         | 264  | Validation cohort | 0 | Consecutive | Original MACS | AMI; MACE | 30 |
| Body; 2016; UK        | Adult | 1577        | 1304 | Validation cohort | 0 | Consecutive | Tro-only | AMI; MACE | 30 |
| Body; 2017; UK        | Adult | 131         | 79   | Validation trial | 0 | Consecutive | Original MACS | MACE | 30-90 |
| Carlton; 2016; UK     | Adult | 782         | 466  | Validation cohort | 0 | Consecutive | Original MACS | AMI; MACE | 30 |
| Greenslade; 2017; Australia/New Zealand | Adult | 1244 | 719 | Validation trial/cohort | 0 | Unclear | Original MACS | AMI; MACE and Tro-only | 30 |
| Va Den Berg; 2018; UK | Adult | 405         | 233  | Validation cohort | 0 | Consecutive | Original MACS | AMI; MACE and Tro-only | 30 |

AMI: Acute myocardial infarction; h-FABP: heart type fatty acid binding protein; HE-MACS: History and electrocardiogram-only Manchester Acute Coronary Syndromes score; MACE: Major adverse cardiac events; MACS: Manchester Acute Coronary Syndromes score; Tro-only: Troponin-only.

Any disagreement was resolved by discussion with the third reviewer.

The collected data included the name of the first author, the year of study, the number of patients (normal, AMI, and MACE), the type of study (derivation and validation), the type of MACS (the original MACS, the troponin-only MACs, and HE-MACS), the assessed outcome (AMI and MACE) and follow-up duration. MACE included all-cause mortality, AMI, and urgent coronary revascularization. Quality assessment of the articles was evaluated using the proposed method of Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) guideline (26).

### 2.4. Statistical analysis

All analyzes were performed in the STATA 14.0 statistical program. Using the values reported in the relevant studies, we calculated true positive, true negative, false positive and false negative. Data were analyzed by “midas” command and the results were reported as a summary receiver operating characteristic (SROC) curve, sensitivity, specificity, positive and negative likelihood ratio, and diagnostic odds ratio with 95% confidence interval (95% CI). The publication bias was evaluated using Deeks’ funnel plot asymmetry test. In all analyzes p <0.05 was considered a significant level.

### 3. Results:

#### 3.1. Characteristics

The search led to the achievement of 3175 non-repetitive records. After the initial screening, 21 articles were studied in detail, and finally, eight papers arrived at the quantitative analysis (4-7, 9, 27-29). Figure 1 illustrates the flow diagram of the present meta-analysis. These eight articles contained 33 separate experiments. There were six cohort arti-
Table 3: Quality assessment of included articles

| Author | Risk of bias | Applicability |
|--------|--------------|---------------|
| Patient Selection | Index Test | Reference Standard | Flow And Timing | Patient Selection | Index Test | Reference Standard |
| Alghamdi; 2018 | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| Body; 2014 | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| Body; 2015 | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| Body; 2016 | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| Body; 2017 | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| Carlton; 2016 | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| Greenslade; 2017 | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| Va Den Berg; 2018 | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |

Q: Low Risk; ☐: High Risk; ?: Unclear Risk

Table 4: Performance of MACS in detection of cardiac events among subgroups

| Subgroup | Number of experiments | AUC (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) | PLR (95% CI) | NLR (95% CI) | DOR (95% CI) |
|----------|-----------------------|--------------|----------------------|----------------------|--------------|--------------|--------------|
| AMI      | Overall               | 15           | 0.99 (0.97-0.99)     | 0.99 (0.98-0.99)     | 0.24 (0.18-0.32) | 1.3 (1.2-1.4) | 0.04 (0.03-0.08) | 29.0 (16.0-55.0) |
| Type of MACS | Original MACS | 8            | 0.99 (0.97-0.99)     | 0.99 (0.98-0.99)     | 0.26 (0.20-0.34) | 1.3 (1.1-1.5) | 0.02 (0.008-0.07) | 31.0 (14.0-68.0) |
| Tro-only and HE-MACS | 7          | 0.99 (0.97-0.99) | 0.99 (0.98-0.99) | 0.22 (0.11-0.37) | 1.5 (1.3-1.7) | 0.03 (0.01-0.07) | 51.0 (16.0-162.0) |
| Type of study | Validation | 4            | 0.99 (0.98-1.0)      | 0.99 (0.98-1.0)      | 0.26 (0.12-0.48) | 1.3 (1.0-1.7) | 0.03 (0.01-0.10) | 42.0 (11.0-163.0) |
|       | Derivation            | 11           | 0.99 (0.97-0.99)     | 0.99 (0.98-0.99)     | 0.24 (0.17-0.32) | 1.3 (1.2-1.4) | 0.05 (0.03-0.10) | 25.0 (13.0-51.0) |
| MACE    | Overall               | 18           | 0.97 (0.95-0.98)     | 0.99 (0.98-0.99)     | 0.25 (0.19-0.32) | 1.3 (1.2-1.4) | 0.05 (0.03-0.09) | 25.0 (13.0-43.0) |
| Type of MACS | Original MACS | 11           | 0.98 (0.97-0.99)     | 0.99 (0.98-0.99)     | 0.27 (0.22-0.33) | 1.4 (1.3-1.5) | 0.05 (0.03-0.09) | 27.0 (14.0-53.0) |
| Tro-only and HE-MACS | 7         | 0.94 (0.92-0.96) | 0.99 (0.97-1.0) | 0.22 (0.12-0.39) | 1.3 (1.1-1.5) | 0.05 (0.02-0.12) | 27.0 (10.0-71.0) |
| Type of study | Validation | 4            | 0.98 (0.96-0.99)     | 0.99 (0.98-1.0)      | 0.27 (0.12-0.49) | 1.4 (1.0-1.8) | 0.03 (0.01-0.08) | 48.0 (16.0-146.0) |
|       | Derivation            | 14           | 0.97 (0.95-0.98)     | 0.98 (0.97-0.99)     | 0.25 (0.19-0.32) | 1.3 (1.2-1.4) | 0.06 (0.04-0.10) | 20.0 (12.0-33.0) |

AMI: Acute myocardial infarction; CI: Confidence interval; AUC: Area under the curve; DOR: Diagnostic odds ratio; HE-MACS: History and electrocardiogram-only MACS; MACE: Major adverse cardiac events; MACS: Manchester Acute Coronary Syndromes score; NLR: Negative likelihood ratio; PLR: Positive likelihood ratio; Tro-only: Troponin-only

3.2. Quality control of articles and risk of bias

The quality assessment showed that the applicability of patient selection was high risk and unclear in two studies. In addition, in one study, the risk of bias in patient selection was unclear. In other cases, the risk of bias were low. Table 3 shows the quality status of the articles. Deeks funnel plot asymmetry test showed that there was no publication bias in the evaluation of the MACS in the rule out of AMI and MACE (Figure 2).

3.3. The value of MACS in rule out of AMI

Data from seven studies (15 separate experiments) included in this section. The analysis showed that the area under the SROC curve of MACS in the rule out of AMI was excellent (AUC = 0.99, 95% CI: 0.97 to 0.99) (Figure 3). The sensitivity and specificity of the MACS decision aid in the diagnosis of AMI were 0.99 (95% CI: 0.98-0.99) and 0.24 (95% CI: 0.18-0.32), respectively. In addition, DOR of this rule out criteria was 29.0 (95% CI: 16.0-55.0) (Figure 4 and Table 4). The sensitivity and specificity of troponin-only MACS / HE-MACS in the diagnosis of AMI was 0.99 (95% CI: 0.98-0.99) and 0.22 (95% CI: 0.11-0.37), respectively. These values for the original
MACS were 0.99 (95% CI: 0.98-0.99) and 0.26 (95% CI: 0.20-0.34), respectively. In the sensitivity (0.99 vs. 0.99) and specificity (0.26 vs. 0.24) of MACS there was no difference between validation and derivation studies (Table 4).

3.4. Diagnostic value of MACS in MACE detection

Data from eight studies (18 separate experiments) were included in this section. The analysis showed that the area under the SROC curve of MACS in the rule out of MACE was excellent (AUC = 0.97, 95% CI: 0.95 to 0.98) (Figure 3). The sensitivity, specificity and DOR of the MACS rule in prediction of MACE were 0.99 (95% CI: 0.98-0.99) and 0.25 (95% CI: 0.19-0.32), and 25.0 (95% CI: 13.0-43.0), respectively (Figure 5 and Table 4). The sensitivity and specificity of the troponin-only MACS / HE-MACS in the rule out of MACE was 0.94 (95% CI: 0.92-0.96) and 0.22 (95% CI: 0.12-0.39), respectively. These values for the original MACS were 0.99 (95% CI: 0.98-0.99) and 0.27 (95% CI: 0.22-0.33) respectively. The sensitivity (0.98 vs. 0.97) and specificity (0.27 vs. 0.25) of MACS were not different in the MACE prediction between the validation and derivation studies (Table 4).

4. Discussion:

The findings of this study showed that the MACS value is good in the screening of AMI and MACE. It was also found that the value of troponin-only / HE-MACS is similar to the original MACS. Since troponin-only MACS and HE-MACS have fewer variables and don’t need to evaluate the heart-type fatty acid binding protein, it seems that the use of troponin-only / HE-MACS is better than the original MACS. The MACS sensitivity to rule out of ACS is very high, but its specificity is low. Therefore, MACS is a good screening tool for AMI diagnosis and MACE prediction. In line with the present review article, Reynard et al. by reviewing five studies concluded that MACS is a good model for rule out of ACS (26). In the present study, 8 articles included in the meta-analysis. Although data from 7658 patients were analyzed, 7 studies were conducted by a team in the UK (4-7, 9, 27, 28). Only one study in Australia and New Zealand performed, that only 405 patients were examined (29). Therefore, exter-
nal validation of MACS in other communities is also required to ensure it is generalized.

The findings of this study indicate that the performance of troponin-only MACS or HE-MACS in rule out of ACS is not different from the original MACS. One of the main disadvantages of the original MACS is the need to evaluate the heart-type fatty acid binding protein (h-FABP), while in the other two models, it is not necessary to measure h-FABP. The value of the troponin-only MACS in rule out of ACS was evaluated in four studies, while the value of HE-MACS was examined only in one study. Since the HE-MACS method does not require measurement of high sensitivity troponin and h-FABP, so if the screening value of HE-MACS is confirmed, it will be easier to use for rule out the ACS. Further studies are needed to achieve this goal.

5. Conclusion

The findings of this study showed that the original MACS, troponin-only MACS, and HE-MACS are capable to rule out AMI and MACE. However, further studies are needed in developing countries for external validation.

6. Appendix

6.1. Acknowledgements

None.

6.2. Authors’ Contributions

MY and FR designed the study. MY, SA, GhF collected the data. MY and AB analyzed the data and interpreted the results. MY and FR wrote the manuscript. All authors critically revised the paper.

Authors’ ORCIDs
Fatemeh Ramezanl: 0000-0001-7359-4880
Sajjad Ahmadi: 0000-0002-7733-5189
Gholamreza Faridalaee: 0000-0002-9990-4936
Alireza Baratloo: 0000-0002-4383-7738
Mahmoud Yousefifard: 0000-0001-5181-4985

6.3. Funding Support

None.

6.4. Conflict of Interest

There was no conflict of interest.

References

1. Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. (2018) Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet 392(10159):1736-88.
2. Shah AS, Anand A, Sandoval Y, Lee KK, Smith SW, Adamson PD, et al. (2015) High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study. The Lancet 386(10012):2481-8.
3. Members ATE, Hamm CW, Bassand J-P, Agewall S, Bax J, Boersma E, et al. (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European heart journal 32(23):2999-3054.
4. Body R, Carley S, McDowell G, Pemberton P, Burrows G, Cook G, et al. (2014) The Manchester Acute Coronary Syndromes (MACS) decision rule for suspected cardiac chest pain: derivation and external validation. Heart (British Cardiac Society) 100(18):1462-8.
5. Body R, Burrows G, Carley S, Lewis PS (2015) The Manchester Acute Coronary Syndromes (MACS) decision rule for suspected cardiac chest pain: validation with a new automated assay for heart-type fatty acid binding protein. Emergency medicine journal : EMJ 32(10):769-74.
6. Body R, Carlton E, Sperrin M, Lewis PS, Burrows G, Carley S, et al. (2017) Troponin-only Manchester Acute Coronary Syndromes (T-MACS) decision aid: single biomarker re-derivation and external validation in three cohorts. Emergency medicine journal : EMJ 34(6):349-56.
7. Va Den Berg P, Burrows G, Lewis P, Carley S, Body R (2018) Validation of the (Troponin-only) Manchester ACS decision aid with a contemporary cardiac troponin I assay. The American journal of emergency medicine 36(4):602-7.
8. Body R (2010) Clinical decision rules for acute coronary syndromes: The specifics. Emergency Medicine Journal 27(12):895.
9. Alghamdi A, Howard L, Reynard C, Moss P, Jarman H, Mackway-Jones K, et al. (2018) Enhanced triage for patients with suspected cardiac chest pain: the History and Electrocardiogram-only Manchester Acute Coronary Syndromes (HE-MACS) decision aid. European journal of emergency medicine : official journal of the European Society for Emergency Medicine.
10. Ahmadi S, Yousefifard M (2017) Accuracy of Pediatric Emergency Care Applied Research Network Rules in Prediction of Clinically Important Head Injuries; A Systematic Review and Meta-Analysis. International Journal of Pediatrics 5(12):6285-300.
11. Ebrahim A, Yousefifard M, Kazemi HM, Rassouli HR, Asady H, Jafari AM, et al. (2014) Diagnostic accuracy
of chest ultrasonography versus chest radiography for identification of pneumothorax: a systematic review and meta-analysis. Tanaffos 13(4):29.
12. Ghelichkhani P, Yousefifard M, Nazemi L, Safari S, Hosseini M, Baikpour M, et al. (2016) The value of serum ß-subunit of human chorionic gonadotropin level in prediction of treatment response to methotrexate in management of ectopic pregnancy; a systematic review and meta-analysis. International Journal of Pediatrics 4(9):3503-18.
13. Hassanzadeh-Rad A, Yousefifard M, Katal S, Asady H, Fard-Esfahani A, Moghadas Jafari A, et al. (2016) The value of 18F-fluorodeoxyglucose positron emission tomography for prediction of treatment response in gastrointestinal stromal tumors: a systematic review and meta-analysis. Journal of gastroenterology and hepatology 31(5):929-35.
14. Hosseini M, Ghelichkhani P, Baikpour M, Tafakhori A, Asady H, Haji Ghanbari MJ, et al. (2015) Diagnostic Accuracy of Ultrasonography and Radiography in Detection of Pulmonary Contusion; a Systematic Review and Meta-Analysis. Emergency (Tehran, Iran) 3(4):127-36.
15. Hosseini M, Yousefifard M, Ataei N, Oraii A, Mirzay Razaz J, Izadi A (2017) The efficacy of probiotics in prevention of urinary tract infection in children: A systematic review and meta-analysis. Journal of pediatric urology 13(6):581-91.
16. Hosseini M, Yousefifard M, Aziznejad H, Nasirinezhad F (2015) The Effect of Bone Marrow-Derived Mesenchymal Stem Cell Transplantation on Allodynia and Hyperalgesia in Neuropathic Animals: A Systematic Review with Meta-Analysis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 21(9):1537-44.
17. Hosseini M, Yousefifard M, Baikpour M, Rahimi-Movaghar V, Nasirinezhad F, Younesian S, et al. (2016) The efficacy of Schwann cell transplantation on motor function recovery after spinal cord injuries in animal models: A systematic review and meta-analysis. Journal of chemical neuroanatomy 78:102-11.
18. Izadi A, Yousefifard M, Nakhjavan-Shahraki B, Baikpour M, Mirzay Razaz J, Ataei N, et al. (2016) Value of plasma/serum neutrophil gelatinase-associated lipocalin in detection of pediatric acute kidney injury; a systematic review and meta-analysis. International Journal of Pediatrics 4(11):3815-36.
19. Izadi A, Yousefifard M, Nakhjavan-Shahraki B, Baikpour M, Mirzay Razaz J, Hosseini M (2016) Diagnostic value of Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) in detection of pediatric acute kidney injury; a systematic review and meta-analysis. International Journal of Pediatrics 4(11):3875-95.
Manchester Acute Coronary Syndromes (T-MACS) rules for the prediction of acute myocardial infarction in patients presenting to the emergency department with chest pain. Emergency medicine journal: EMJ 34(8):517-23.